An Early Phase 1 interventional study of Akkermansia Muciniphila, Clostridium Beijerinckii, Anaerobutyricum Hallii, Clostridium Butyricum, Bifidobacterium Infantis Probiotic Capsule in Acne, sponsored by Medical University of South Carolina. Not yet recruiting. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-05-12.
Sponsored by Medical University of South Carolina · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The project explores the use of Pendulum's Glucose Control, which contains a unique combination of probiotics, including Akkermansia muciniphila, Clostridium beijerinckii, Anaerobutyricum hallii, Clostridium butyricum, and Bifidobacterium infantis, to treat acne by improving gut health and reducing inflammation. These probiotic strains work synergistically to enhance the gut's protective barrier, lower harmful substances such as lipopolysaccharides, and increase the production of beneficial compounds like short-chain fatty acids, which can help modulate immune response and inflammation associated with acne. By integrating this probiotic combination into treatment strategies, the approach aims to offer a natural and effective solution for clearer skin. Additionally, the project seeks to investigate the correlation between postprandial glucose spikes and acne flare-ups. Continuous glucose monitoring (CGM) will be employed to track blood glucose fluctuations following meals, providing valuable insights into the potential link between metabolic responses and acne severity. This comprehensive approach aims to enhance understanding of how gut health, inflammation, and metabolic factors interact in the context of acne management.
Akkermansia muciniphila, Clostridium beijerinckii, Anaerobutyricum hallii, Clostridium butyricum, and Bifidobacterium infantis are emerging as promising candidates for next-generation probiotics with potential applications in the management of acne. These microorganisms have been recognized for their roles in enhancing gut barrier function and contributing to a healthy gut microbiota composition. Through mechanisms such as strengthening the gut mucosal barrier and reducing systemic lipopolysaccharide levels, these probiotics may help mitigate systemic inflammation and lower inflammatory markers. Additionally, their capacity to produce short-chain fatty acids, including acetate, propionate, and butyrate, may contribute to immune modulation and a reduction in inflammatory processes, which are relevant to acne pathogenesis. This evidence highlights the potential utility of these probiotics in therapeutic strategies aimed at improving acne outcomes via modulation of the gut microbiota.
In this study, investigators also aim to explore the relationship between postprandial glucose spikes and acne flare-ups. To investigate this, investigators will utilize continuous glucose monitoring (CGM) to track fluctuations in blood glucose levels following meals. By correlating these glucose spikes with changes in acne severity, investigators hope to gain a deeper understanding of the potential connection between metabolic responses and inflammatory skin conditions. This approach will provide valuable insight into how dietary factors and gut microbiota modulation may interact to influence acne outcomes.
795 studies on the registry are indexed under Acne Vulgaris; 96 are open to participants now.
This study's planned enrollment of 34 is below the median of 70 across 676 interventional studies indexed under Acne Vulgaris.
Browse Acne Vulgaris studies →Medical University of South Carolina is the lead sponsor of 875 studies on the registry; 165 are open to participants now.
Of its 132 completed or terminated interventional studies of FDA-regulated products, 104 (79%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a 12-week probiotic course.
Dietary Supplement: Akkermansia Muciniphila, Clostridium Beijerinckii, Anaerobutyricum Hallii, Clostridium Butyricum, Bifidobacterium Infantis Probiotic Capsule
Probiotic capsule will contain Akkermansia Muciniphila, Clostridium Beijerinckii, Anaerobutyricum Hallii, Clostridium Butyricum, and Bifidobacterium Infantis
Acne severity reduction
The primary outcome measure will be the reduction in acne severity from baseline, as assessed by a validated acne severity scoring system (the Global Acne Grading System). Acne severity will be evaluated based on the number, type, and distribution of lesions, as well as the overall clinical assessment of the skin condition. Assessments will be conducted at baseline and specified follow-up intervals to determine the extent of improvement. Reduction in severity will be quantified as a percentage change from baseline scores.
Time frame: 12 weeks
Association Between Postprandial Glucose Spikes and Acne Flares
The secondary outcome measure will evaluate the association between postprandial glucose spikes and the frequency or severity of acne flares. Postprandial glucose levels will be monitored using continuous glucose monitoring at designated intervals. Acne flares will be assessed using a validated acne severity scoring system along with participant journals, with flare frequency and changes in lesion count/type recorded over the study period. Correlations between glucose spike magnitude and acne flare characteristics will be analyzed to identify potential relationships.
Time frame: 12 weeks
No study locations are listed for this record.
Start is estimated for Mar 2027; primary completion for Dec 2028, 21 months later.
Of 51 phase 1 interventional studies under Acne Vulgaris, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 10. This study's planned 21 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of South Carolina →